News & Events

August 26, 2011

IntegriChain Launches End to End Channel Data Platform


Princeton, NJ – August 28, 2011 – IntegriChain, Inc., a next generation life sciences informatics company, today announced a major release of its DNA: Demand Network Analytics™ platform.

The new version of DNA will deliver pharma, biopharma, and generics manufacturers a single DaaS (Data as a Service) solution for the integration, enrichment, reporting and analysis of specialty and wholesale channel data. Already a widely used platform for EDI 867 and EDI 852 analytics and pharmacy inventory reporting, DNA’s latest release adds support for direct processing of data from wholesalers, specialty distributors, specialty pharmacies and hubs.

Other data sets processed in DNA include reconciled chargebacks (EDI 849), third party returns (EDI 180), purchase orders (EDI 850), manufacturers’ ex-factory sales, and anonymized patient level data reported by specialty pharmacies. DNA includes web-based tools for ad-hoc data mining, reporting, and exception monitoring. DNA’s latest version also includes increased support for integration with customer data warehouses and CRM systems.

“Channel data plays an increasingly critical role in our customers’ commercial operations, from financial reporting to promotion measurement and sales compensation,” said Daniel Kinney, IntegriChain’s VP of Information Services. “Our new release of DNA helps our customers consolidate their channel data silos in a single platform that supports the full range of their business applications.”

Kevin Leininger, IntegriChain CEO, highlighted DNA’s unique combination of master data management, data enrichment, and data hosting. “Traditionally, manufacturers have been forced to work with multiple systems and vendors to manage their channel data flows, integrate customer and product lists, and add key customer dimensions such as demographics, business classifications and account relationships. In DNA, IntegriChain has created the industry’s first platform that combines these services in a single secure, hosted environment. DNA significantly lowers customers total cost of ownership in utilizing the channel data assets they already own.”

IntegriChain will be demonstrating its new DNA release at this year’s NACDS Pharmacy Technology Expo in Boston, August 27th through August 30th.

About IntegriChain
IntegriChain, Inc. launched the Demand Network Analytics (DNA) commerce platform in 2007. Today, DNA is helping a growing community of innovative manufacturers realize their vision of a truly demand driven enterprise. DNA’s trade data management and analytic applications optimize hundreds of billions of dollars in annual commerce, helping manufacturers lower their distribution costs, improve sales predictability, and ensure product availability throughout their distribution channels. For more information, please visit

All names referred to are trademarks or registered trademarks of their respecitve owners.

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand